Kura Oncology Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hey, everybody. It is Alethia Young here. I cover large-cap, small/mid-cap biotech at Cantor. I'm very happy to have Kura Oncology here with me, Dr. Troy Wilson, who is the President and CEO. So we will be doing a fireside chat for the next 30 minutes. And what I want to first do is let Troy frame the Kura story, and then we will dig into detail on the key products. So with that, Troy, please go ahead.
Sure. Alethia, thank you to you and the Cantor team for the opportunity to participate in the fireside chat and in the conference. So at Kura Oncology, we are now advancing three pillars, all in the area of precision medicine and oncology. The first is our menin-MLL inhibitor for the treatment of genetically defined subtypes of acute leukemia. That program is in a Phase 1b study.
The next program is tipifarnib, which is an inhibitor of the farnesyl transferase enzyme. That program is in a registration directed study in HRAS mutant head and neck cancer. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |